Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Lymphoma, Large Cell, Diffuse Clinical Trial

Official title:

Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00322218
• Other study ID #: 307940/106-20
• Status: Terminated
• Phase: Phase 3
• Start date: May 2006
• Est. completion date: December 2008

Study information

• Verified date: January 2022
• Source: Spectrum Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study treats patients with diffuse large B-cell lymphoma whose disease is in complete remission due to previous treatment with Cyclophosphamide Doxorubicin hydrochloride Vincristine Prednisolone- Rituximab (CHOP-R). Half of the patients received Zevalin and the other half receive no further anti-cancer treatment. The two patient groups compared to determine if Zevalin given after CHOP-R therapy provides greater benefits than receiving no additional anti-cancer therapy after CHOP-R.

Description:

The objectives of this study were to evaluate the efficacy and safety of the Zevalin study regimen compared with observation alone in patients with complete remission (CR or CRu) after first-line CHOP-R, the study was to include patients 60-years-of-age or older with histologically confirmed Ann Arbor stage II, III, or IV diffuse large B-cell lymphoma

End Points:

Primary endpoint: Overall survival (OS) Secondary endpoints: Disease-free survival (DFS), health-related quality of life (HRQL) as assessed by the patient using standard questionnaires .

Number of Patients :

A total of 400 patients (200 per arm) were planned to be enrolled.

• In fact, 68 randomized patients (full analysis set; FAS) were analysed; 34 patients per each arm. The per-protocol set (PPS; 65 patients) comprised 33 patients allocated to the Zevalin arm and 32 patients allocated to the observation control arm.

Study Treatment :

The combination regimen with rituximab was designed in 2 steps as follows:

• Day 1: Initial administration of 250 mg/m^2 rituximab, followed immediately by administration of 185 megabecquerel (MBq) (5 millicurie [mCi]) of [111In]-ibritumomab tiuxetan (the latter one only in centers where biodistribution imaging or dosimetry was compulsory according to local law). In centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.

• Day 7-9: Rituximab 250 mg/m^2, followed immediately by [90Y]-ibritumomab tiuxetan 14.8 megabecquerel/kilograms (MBq/kg) (0.4 millicurie / kilogram [mCi/kg]) (maximum dose 1184 MBq) given as a slow intravenous (I.V.) push over 10 minutes. Two treatment days one week apart followed by a 12-week safety period.

Duration of Patient Participation:

Due to the sequential design, the total duration of this study was not fixed. Originally, the study was planned in a randomized, parallel-group, group sequential design.

Objective :

The primary objective of this study was an inferential comparison between the 2 randomized groups in terms of overall survival using a group sequential triangular test ,since the study was prematurely terminated the pre-planned group-sequential nature of the study design was not applicable statistical analyses. Actually, the prominent efficacy variables for the OS and DFS were analysed in the FAS (identical to the safety analysis set) and PPS using Kaplan Meier estimates by treatment group.

Study Design :

This study was designed as a prospective, multi-center, open label, randomized, two-armed, group-sequential Phase III study. The study was planned to consist of 2 stages: an interventional Stage 1 with Screening/Baseline, treatment, safety, and follow-up periods, and a non-interventional Stage 2 consisting of a long-term follow-up period (until completion of a median observation period of 5 years). This second stage of the study was to be started only if superiority of the Zevalin study regimen could be demonstrated in the preceding Stage 1.

Pharmacokinetics/Pharmacodynamic results: Not applicable

Extent of exposure:

All 34 patients randomized to the Zevalin arm were given 2 rituximab infusions(with a median dose of 425.0 mg at each of the 2 infusion time points).Three patients underwent radioimaging studies/dosimetry and therefore were administered [111In]-ibritumomab tiuxetan at Day 1. All but 1 patient received an infusion with [90Y]-ibritumomab tiuxetan following the second infusion of rituximab. The mean dose ranged from 765.9 -1197.0 MBq.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 68
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed, Ann Arbor stage II, III, or IV Diffuse large B-cell lymphoma (DLBCL) according to the Revised European American Lymphoma(REAL)/World Health Organization (WHO) classification .

• Central pathology review confirming the DLBCL diagnosis and Cluster of differentiation 20 (CD20) positivity, and no evidence of DLBCL in bone marrow

• First-line treatment of DLBCL must have been 6 or 8 cycles of standard CHOP chemotherapy in combination with rituximab .

• Complete remission(CR) or unconfirmed complete remission(CRu) according to the International Workshop Response Criteria for Non Hodgkins Lymphoma (NHL) described by Cheson et al and modified for this study after first-line treatment with CHOP-R. Computerised Tomography (CT) scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of CHOP-R. Applicability of the neck CT means that the patient had involvement of the neck region by palpation / physical examination at first diagnosis (pre-CHOP-R).

• Central radiographic review of the CT scans from before and after first-line treatment with CHOP-R fulfilling the radiological requirements for CR/CRu

• Patients 60 years of age or older at time of randomization

• WHO performance status (PS) of 0 to 2 within 1 week of randomization

• Absolute neutrophil count greater than or equal to 1.5 x 10^9/L within 1 week of randomization

• Hemoglobin greater than or equal to 10 g/dL within 1 week of randomization

• Platelets greater than or equal to 150 x 10^9/L within 1 week of randomization

• Life expectancy of 3 months or longer

• Written informed consent obtained according to local guidelines

Exclusion Criteria:

• Presence of any other malignancy or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma

• Prior radioimmunotherapy, radiation therapy, or any other NHL therapy except first-line CHOP-R

• Presence of gastric, central nervous system or testicular lymphoma at first diagnosis

• Histological transformation of low-grade non-Hodgkin's lymphoma (NHL)

• Known seropositivity for hepatitis C virus or hepatitis B surface antigen

• Known history of Human Immunodeficiency virus (HIV) infection

• Abnormal liver function: total bilirubin > 1.5 x upper limit of normal (ULN) or Alanine Aminotransferase > 2.5 x ULN within 1 week of randomization

• Abnormal renal function: serum creatinine > 2.0 x ULN within 1 week of randomization

• Nonrecovery from the toxic effects of CHOP-R therapy

• Known hypersensitivity to murine or chimeric antibodies or proteins

• Granulocyte Colony Stimulating Factor (G-CSF) or Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) therapy within two weeks (or four weeks if pegylated) prior to screening laboratory sampling

• Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study

• Male and female patients of child-bearing potential unwilling to practice effective contraception during the study and unwilling or unable to continue contraception for 12 months after their last dose of study treatment

• Female patients who are pregnant or are currently breastfeeding

• Treatment with investigational drugs less than 4 weeks before the planned Day 1 or nonrecovery from the toxic effects of such therapy

• Surgery less than 4 weeks before the planned Day 1 or nonrecovery from the side effects of such surgery

• Concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment

• Unwillingness or inability to comply with the protocol

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Large Cell, Diffuse

Intervention

Drug:
• Zevalin
Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one [90Y]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion. The core treatment regimen in the Zevalin arm was: Day 1: Rituximab i.v. infusion 250 mg/m^2 Day 7-to 9: Rituximab i.v. infusion 250 mg/m^2 immediately followed by [90Y]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes.

Locations

Country	Name	City	State
Austria	Research Site	Graz
Austria	Research Site	Innsbruck
Belgium	Research Site	Brugge
Belgium	Research Site	Gent
Belgium	Research Site	Leuven
Canada	Research Site	Edmonton	Alberta
Canada	Research Site	Montreal	Quebec
Canada	Research Site	Ottawa	Ontario
Canada	Research Site	Toronto	Ontario
Finland	Research Site	Helsinki
Finland	Research Site	Oulu
France	Research Site	Creteil
France	Research Site	Dijon
France	Research Site	Lille Cedex
France	Research Site	Limoges
France	Research Site, Cedax	Lyon
France	Research Site	Paris Cedex
France	Research Site	Toulouse Cedex
Germany	Research Site	Chemnitz
Germany	Research Site	Jena
Germany	Research Site	Karlsruhe
Germany	Research Site	Mainz
Germany	Research Site	Rostock
Germany	Research Site	Wurzburg
Hungary	Research Site	Budapest
Hungary	Research Site	Debrecen
Hungary	Research Site	Szeged
Ireland	Research Site	Dublin
Ireland	Research Site	Galway
Italy	Research Site	Bologna
Italy	Research Site	Milan
Italy	Research Site	Perugia
Italy	Research Site	Pisa
Italy	Research Site	Torino
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site, Yonsei	Seoul
Poland	Research Site	Gdansk
Poland	Research Site	Krakow
Poland	Research Site	Poznan
Poland	Research Site	Warsaw
Portugal	Research Site	Coimbra
Portugal	Research Site	Lisbon
Portugal	Research Site	Porto
Singapore	Research Site	Singapore
Spain	Research Site	Madrid
Spain	Research Site	Pamplona
Spain	Research Site	Salamanca
Spain	Research Site	Sevilla
Sweden	Research Site	Malmo
Sweden	Research Site	Uddevalla
Sweden	Research Site	Umea
Switzerland	Research Site	Bern
Switzerland	Research Site	St Gallen
Thailand	Research Site	Bangkok
United Kingdom	Research Site	Leicester
United Kingdom	Research Site	London
United States	Research Site	Aberdeen	South Dakota
United States	Research site	Aurora	Colorado
United States	Research site	Bakersfield	California
United States	Research site	Baltimore	Maryland
United States	Research Site	Berkeley	California
United States	Research Site	Beverly Hills	California
United States	Research site	Boston	Massachusetts
United States	Research Site	Burbank	California
United States	Research site	Chicago	Illinois
United States	Research Site	Coeur d'Alene	Idaho
United States	Research Site	Commack	New York
United States	Research Site	Dallas	Texas
United States	Research site	Detroit	Michigan
United States	Research Site	Duarte	California
United States	Research Site	Durham	North Carolina
United States	Research Site	East Setauket	New York
United States	Research Site	Houston	Texas
United States	Research site	Joliet	Illinois
United States	Research site	Los Angeles	California
United States	Research Site	Mesa	Arizona
United States	Research Site	Morris	Illinois
United States	Research site	Newark	Delaware
United States	Research site	Newport Beach	California
United States	Research Site	Norfolk	Virginia
United States	Research site	Overland Park	Kansas
United States	Research Site	Philadelphia	Pennsylvania
United States	Research Site	Phoenix	Arizona
United States	Research Site	Rochester	Minnesota
United States	Research Site	Saint Louis Park	Minnesota
United States	Research site	Saint Petersburg	Florida
United States	Research Site	San Diego	California
United States	Research Site	Scottsdale	Arizona
United States	Research Site	Shreveport	Louisiana
United States	Research site	Vallejo	California

Sponsors (2)

Lead Sponsor	Collaborator
Spectrum Pharmaceuticals, Inc	Bayer

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Canada,  Finland,  France,  Germany,  Hungary,  Ireland,  Italy,  Korea, Republic of,  Poland,  Portugal,  Singapore,  Spain,  Sweden,  Switzerland,  Thailand,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	The primary analysis was based on the full analysis set (FAS). Actually, the prominent efficacy variable OS was analysed in the FAS (identical to the safety analysis set) and Per Protocol Set using Kaplan Meier estimates by treatment group. "Overall survival" was defined as the median time interval (in months)from randomization to death from any cause.This time-to-event variable was censored at the date of the last known follow-up visit (provided that the patient was still alive at that time).	5 years or until patient dies or lost to follow up
Secondary	Proportion of Participants With Disease Free Survival (DFS)	DFS was analysed in the FAS (identical to the safety analysis set) and Per Protocol set using Kaplan Meier estimates by treatment group.Disease-free survival was defined as the median time interval (in months) from randomization to the date of relapse (as assessed by the investigator) or death from any cause. This time-to-event variable was also censored at the date of the last known follow-up visit (provided that the patient was still alive at that time).	5 years or until patient disease progresses or lost to follow up
Secondary	The Health-related Quality of Life (HRQL)	HRQL questionnaire consists of 27 questions each scores ranging from 0 - 4. The minimum score was 0 which is termed as 'worst imaginable health state' and the maximum score for a patient was 100 which is termed as 'best imaginable health state'.; The descriptive classification defines health status in terms of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension is subdivided into 3 levels: no problem, some or moderate problems, unable or extreme problems.	Up to Month 36